GATC Biotech

The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "GATC Biotech" – news · newspapers · books · scholar · JSTOR (March 2014) (Learn how and when to remove this template message)

GATC Biotech was a German company specialist in

Founded in 1990 the company concentrated in the early days on commercialising a nonradioactive sequencing technology platform,[1] patented by Prof. Pohl, one of the founders of GATC.

The direct blotting electrophoresis system, the GATC 1500 was utilised in the European Saccharomyces cerevisiae^[2] genome project. In 1996 started the transformation from an instrument manufacturer to a service provider in the field of DNA and RNA sequencing. As part of the Gene Alliance, founded in 1998, the company was involved in the large-scale genome analysis project Aspergillus niger funded by DSM (The Netherlands) and finished in 2001.^[3]

In 2006 the company started to develop the next generation sequencing business division adding the Europe's first commercial PacBio RS platform in 2011.

In July 2017 GATC Biotech was acquired by Eurofins Genomics (part of Eurofins Scientific).

Structure of the company

GATC Biotech was a limited company and had several subsidiaries in Europe.

• GATC Biotech AB, Stockholm, Sweden (100%)
• GATC Biotech Ltd., Cambridge, United Kingdom (100%)
• GATC Biotech SARL, Marseille, France (100%)

Products

The range of products covers the Sanger sequencing applications^[4] as well as next generation sequencing, such as de novo sequencing, human exome sequencing for clinical settings and RNA-Seq.^{[citation needed]}

References